Stockholders' Equity	6 Months Ended
Jun. 30, 2020
Equity [Abstract]
Stockholders' Equity	9. Stockholders’ Equity In June 2020, as a result of the completion of the one-year vesting period, an aggregate of 24,000 restricted stock units of members of the Board of Directors vested and were settled in shares of the Company’s common stock (see Note 13, Stock-Based Compensation). In April and June 2020, as a result of the achievement of certain performance targets, an aggregate of 95,834 restricted stock units of various executive officers vested and were settled in shares of the Company’s common stock (see Note 13, Stock-Based Compensation). In May 2019, as a result of the achievement of a clinical performance target, an aggregate of 74,166 restricted stock units of various executive officers vested and were settled in shares of the Company’s common stock (see Note 13, Stock-Based Compensation). On March 20, 2019, or the Effective Date, the Company entered into a consulting agreement with an existing stockholder. In accordance with the agreement, the stockholder provided various consulting services to the Company in exchange for 10,195 unregistered shares of the Company’s common stock. The closing price of the Company’s common stock on the Effective Date was $19.37 per share. The services provided by the consultant were performed during the six-month period following the Effective Date. The Company recorded a prepaid expense of $197 with a corresponding offset to Additional Paid-In Capital during the six months ended June 30, 2019. The Company amortized the entire amount of the prepaid expense on a straight-line basis as stock compensation expense within general and administrative expense over the six-month period in 2019 as services were performed. During the three and six months ended June 30, 2019, $99 of stock-based compensation expense was recognized as stock compensation expense in the Condensed Statement of Comprehensive Loss, all of which was related to G&A expense.

Stockholders' Equity

6 Months Ended

Jun. 30, 2020

9. Stockholders’ Equity

In June 2020, as a result of the completion of the one-year vesting period, an aggregate of 24,000 restricted stock units of members of the Board of Directors vested and were settled in shares of the Company’s common stock (see Note 13, Stock-Based Compensation).

In April and June 2020, as a result of the achievement of certain performance targets, an aggregate of 95,834 restricted stock units of various executive officers vested and were settled in shares of the Company’s common stock (see Note 13, Stock-Based Compensation).

In May 2019, as a result of the achievement of a clinical performance target, an aggregate of 74,166 restricted stock units of various executive officers vested and were settled in shares of the Company’s common stock (see Note 13, Stock-Based Compensation).

On March 20, 2019, or the Effective Date, the Company entered into a consulting agreement with an existing stockholder. In accordance with the agreement, the stockholder provided various consulting services to the Company in exchange for 10,195 unregistered shares of the Company’s common stock. The closing price of the Company’s common stock on the Effective Date was $19.37 per share. The services provided by the consultant were performed during the six-month period following the Effective Date. The Company recorded a prepaid expense of $197 with a corresponding offset to Additional Paid-In Capital during the six months ended June 30, 2019. The Company amortized the entire amount of the prepaid expense on a straight-line basis as stock compensation expense within general and administrative expense over the six-month period in 2019 as services were performed. During the three and six months ended June 30, 2019, $99 of stock-based compensation expense was recognized as stock compensation expense in the Condensed Statement of Comprehensive Loss, all of which was related to G&A expense.